A detailed history of Marshall Wace, LLP transactions in Immunome Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 1,216,182 shares of IMNM stock, worth $11.6 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,216,182
Previous 1,467,410 17.12%
Holding current value
$11.6 Million
Previous $21.5 Million 41.84%
% of portfolio
0.02%
Previous 0.03%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025

SELL
$9.11 - $14.53 $2.29 Million - $3.65 Million
-251,228 Reduced 17.12%
1,216,182 $12.5 Million
Q3 2024

Nov 14, 2024

SELL
$11.7 - $16.51 $2.88 Million - $4.06 Million
-245,915 Reduced 14.35%
1,467,410 $21.5 Million
Q2 2024

Aug 14, 2024

BUY
$11.54 - $22.11 $13.8 Million - $26.4 Million
1,191,774 Added 228.51%
1,713,325 $20.7 Million
Q1 2024

May 15, 2024

BUY
$11.01 - $27.34 $5.74 Million - $14.3 Million
521,551 New
521,551 $12.9 Million
Q1 2022

May 16, 2022

SELL
$3.88 - $13.99 $41,337 - $149,049
-10,654 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$12.96 - $23.44 $29,885 - $54,052
2,306 Added 27.62%
10,654 $138,000
Q3 2021

Nov 15, 2021

BUY
$12.5 - $27.76 $104,350 - $231,740
8,348 New
8,348 $203,000

Others Institutions Holding IMNM

About Immunome Inc.


  • Ticker IMNM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,127,400
  • Market Cap $115M
  • Description
  • Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...
More about IMNM
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.